435 related articles for article (PubMed ID: 18181717)
1. Development of probiotics as biologic drugs.
Hoffman FA
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
[TBL] [Abstract][Full Text] [Related]
2. Environmental assessment requirements for live biological drugs.
Sutton A
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
[TBL] [Abstract][Full Text] [Related]
3. Health-benefit claims for probiotic products.
Heimbach JT
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S122-4; discussion S144-51. PubMed ID: 18181716
[TBL] [Abstract][Full Text] [Related]
4. Clinical research on probiotics: the interface between science and regulation.
Tamayo C
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S101-3; discussion S144-51. PubMed ID: 18181711
[TBL] [Abstract][Full Text] [Related]
5. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
[TBL] [Abstract][Full Text] [Related]
6. The US Food and Drug Administration and probiotics: regulatory categorization.
Degnan FH
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
[TBL] [Abstract][Full Text] [Related]
7. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
Tremaine WJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
[TBL] [Abstract][Full Text] [Related]
8. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
9. Current regulatory and legal considerations for follow-on biologics.
Kingham RF; Lietzan E
Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
[No Abstract] [Full Text] [Related]
10. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
11. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
Looper YJ
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
[TBL] [Abstract][Full Text] [Related]
12. Product development of probiotics as biological drugs.
Sutton A
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
[TBL] [Abstract][Full Text] [Related]
13. US Food and Drug Administration regulations governing label claims for food products, including probiotics.
Saldanha LG
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S119-21; discussion S144-51. PubMed ID: 18181715
[TBL] [Abstract][Full Text] [Related]
14. A consensus conference on complex biologics and low molecular weight heparins.
Kalodiki E; Fareed J; Tapson VF; Hoppensteadt DA; Sussman I; Carter CA; Parker S; Harenberg J; Hull R; Rao G; Lovinger DF; Ried LD; Kakkar A; Talarico L; Ofuso F; Bussey HI; Fanikos J; Groce JB; Skinner N; Ahluwalia M; Iqbal O; Jackson CM; Jeske WP; Georges M; Ramacciotti E; Tapson VF; Van Thiel D; Wahi R; Walenga J
Int Angiol; 2010 Apr; 29(2):193-6. PubMed ID: 20351676
[No Abstract] [Full Text] [Related]
15. Missing data issues at the FDA Center for Biologics Evaluation and Research.
Scott JA; Hsu H
J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
[TBL] [Abstract][Full Text] [Related]
16. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
17. Hazard identification and risk assessment for biologics targeting the immune system.
Weir AB
J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
[TBL] [Abstract][Full Text] [Related]
18. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
Kweder SL
Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
[No Abstract] [Full Text] [Related]
19. Scientific and regulatory considerations on the immunogenicity of biologics.
Shankar G; Shores E; Wagner C; Mire-Sluis A
Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
[TBL] [Abstract][Full Text] [Related]
20. The issue of extralabel drug use.
Kennedy JA
J Am Vet Med Assoc; 1997 Dec; 211(11):1354. PubMed ID: 9394877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
